Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-U trial of aspirin and intensive blood pressure control for unruptured intracranial aneurysms
NL-OMON52612Phase 3Recruiting
- Sponsor
- Medical Faculty Mannheim of Heidelberg University
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin in brain aneurysm (IA), sponsored by Medical Faculty Mannheim of Heidelberg University. Primary endpoint: Aneurysm rupture or growth at 36 ± 6 months. Started Apr 2018; status: recruiting.
02
Drugs
aspirin
03
Conditions
brain aneurysm (IA)
Beyond the preview
Go deeper on NL-OMON52612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52612.